Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Shionogi of Japan to Take Control of China’s C&O Pharma

publication date: Aug 1, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shionogi & Co., a Japanese pharma, will pay $185 million to obtain a controlling interest in C&O Pharmaceutical Technology. C&O Pharma, a company that produces antibiotics and other drugs for the China market, is headquartered in Hong Kong, but listed in Singapore. Shionogi said it wants to establish a major presence in China for its own drugs. More details....

Stock Symbol: (TO: 8053)     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



ChinaBio® Events
Partner Events

Shanghai, China
November 1-3, 2016

Shanghai, China
October 18-19, 2016

Del Mar, USA
October 1st, 2016

Del Mar, USA
October 1st, 2016

>> More events...